News | 10 October 2025
Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Panacea Biotec receives acceptance from CMSS for supply of bOPV
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Medico Remedies receives order worth US$ 1,781,000
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
Subscribe To Our Newsletter & Stay Updated
